Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

SHIRE PHARMACEUTICALS PORTUGAL, LDA

NIF 509264662
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €2,270,575 27 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €2,270,575 27 contracts
A2 · Late Publication €1,377,522,559 301 contracts
Contract published to BASE more than 10 days after the signing date
LOW €1,377,522,559 301 contracts
A5 · Threshold Splitting €164,562 2 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €164,562 2 contracts
A9 · Abnormal Price Reduction €1,373,384,876 60 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €1,373,384,876 60 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

49
€358,324,942
5
€357,700,016
48
€309,370,390
2
€299,629,349
98
€22,325,570
4
€17,584,482
5
€10,094,658
17
€9,606,425
30
€8,489,512
43
€2,857,059
2
€1,871,312
11
€1,496,750
5
€910,009
3
€792,717
7
€658,133
15
€361,292
1
€274,680
7
€246,674
3
€215,970
3
€201,588
Page 1 of 2 · 31 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A9 · Abnormal Price Reduction

Page 1 of 1 · 27 contracts

Aquisição de RURIOCTOCOG ALFA PEGOL 500 U.I. PÓ SOL INJ FR IV e RURIOCTOCOG ALFA PEGOL 1000 U.I. PÓ SOL INJ FR IV
PT · 6440017 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€158,903 2020-03-02
Imunoglobulina humana normal 100 mg/ml
PT · 6584989 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€9,477 2020-01-02
Imunoglobulina humana normal 100 mg/ml
PT · 6435452 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€9,477 2019-12-31
Imunoglobulina humana normal 100 mg/ml
PT · 6290140 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€9,477 2019-08-07
Imunoglobulina humana normal 100 mg/ml
PT · 6290111 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€22,671 2019-08-07
Aquisição do medicamento Octocog Alfa 1500UI pó sol inj fr iv
PT · 5612524 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€28,041 2019-05-03
Aquisição de Medicamentos – Imunoglobulina humana normal
PT · 5631849 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€22,745 2019-04-22
Aquisição de medicamento - Pegaspargase
PT · 5479011 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€14,950 2019-01-07
Aquisição de medicamentos - Pegaspargase
PT · 5152762 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€44,852 2018-12-28
Aquisição de OCTOCOG ALFA 500 U.I. PÓ SOL INJ FR IV - A.12002818
PT · 4816512 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€14,644 2018-05-21
Medicamentos do foro oncológico - C/ Base no CPA 2014/6
PT · 2293147 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2015-01-22
Anagrelida 0,5mg comprimidos
PT · 1318380 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€5,847 2014-10-08
aquisição medicamentos
PT · 1900706 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€5,982 2014-07-04
ANAGRELIDA 0,5MG CAPS
PT · 1883723 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€1,252 2014-05-27
Aquisição de Medicamentos Diversos
PT · 1865176 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€15,187 2014-04-23
Aquisição medicamentos diversos
PT · 1865169 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€6,343 2014-03-21
AS 1780/2013 Medicamentos: Velaglucerase alfa 400U pó sol inj Idursulfase 6mg/3ml sol inj Fr IV
PT · 817117 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2013-06-25
AS 1780/2013 Medicamentos: Velaglucerase alfa 400U pó sol inj Idursulfase 6mg/3ml sol inj Fr IV
PT · 5213c0f587c68e907633 · Ajuste direto
A2 · Late Publication A1 · Repeat Direct Award
€292,447 2013-06-25
Medicamentos para Patologias Raras
PT · 761156 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€193,437 2013-04-23
Medicamento-Velaglucerase
PT · 761587 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2013-04-19
Anagrelida 0.5 mg Cáps
PT · 670674 · Ajuste Direto Regime G...
A1 · Repeat Direct Award
€0 2013-01-21
Anagrelida 0.5 mg cáps
PT · 689241 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€0 2013-01-12
Aquisição de Medicamentos diversos
PT · 729925 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€66,000 2012-12-03
Aquisição de 10000 cáps de Anagrelida 0.5 mg Cáps
PT · 726380 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€792,717 2012-11-30
Aquisição de medicamentos diversos
PT · 618441 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€66,000 2012-10-31
Aquisição de Medicamentos diversos
PT · 580338 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication
€66,000 2012-09-26
Medicamento Idursulfase 6mg/3ml Sol. Inj. frs. IV
PT · 484d93fa0bfbc4f8ca9c · Ajuste direto
A2 · Late Publication A1 · Repeat Direct Award
€424,125 2011-08-30
Overview
Total Value Won
€1,403,686,516
Contracts Won
388
Score 14060 · CRITICAL RISK
NIF
509264662
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • M.T. [P-b9ab]
    Gerente
    since 2010-01-21
  • P.S. [P-1db3]
    Gerente
    since 2017-12-14
  • S.I. [P-3c0d]
    Gerente
    since 2019-09-02
  • S.G. [P-1d69]
    Gerente
    since 2018-06-25
  • S.P. [P-4617]
    Sócio
    since 2010-01-21
  • S.P. [P-4617]
    Sócio
    since 2010-02-23
  • S.P. [P-ce20]
    Sócio
    since 2010-01-21
  • S.P. [P-ce20]
    Sócio
    since 2010-02-23
  • A.M. [P-3c7b]
    Gerente
    2015-10-21 → 2017-03-24
  • F.B. [P-34ed]
    Gerente
    2019-01-09 → 2019-09-03
  • H.A. [P-b817]
    Gerente
    2010-01-21 → 2017-03-27
  • J.B. [P-1ffe]
    Gerente
    2014-04-24 → 2015-09-25
  • J.G. [P-6b70]
    Gerente
    2010-01-21 → 2013-12-12
  • M.T. [P-b9ab]
    Gerente
    until 2017-12-14
  • R.L. [P-b800]
    Gerente
    2017-12-14 → 2019-01-09
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned